Working... Menu

MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03778619
Recruitment Status : Recruiting
First Posted : December 18, 2018
Last Update Posted : December 19, 2018
Information provided by (Responsible Party):
Green Cross LabCell Corporation

Brief Summary:
To determine the efficacy and safety of combined therapy of determined MG4101 dose and Rituximab.

Condition or disease Intervention/treatment Phase
Relapsed Non Hodgkin Lymphoma Refractory Non-Hodgkin Lymphoma Drug: Rituximab Drug: Fludarabine Drug: Cyclophosphamide Biological: MG4101(allogeneic Natural Killer cell) Drug: Interleukin-2 Phase 1 Phase 2

Detailed Description:

This trial will consist of 3 parts; Phase 1 Maximum Tolerated Dose, Phase 1 extended cohort and Phase 2a.

For Phase 1, those who have a confirmed diagnosis of relapsed/refractory Non-Hodgkin's Lymphoma (NHL) of B-cell Origin of any subtype will be considered eligible for enrolment. Each cycle last approximately 28 days.

Once the dose of MG4101 is determined from Phase 1, Phase 2a will commence whereby two subgroups of patients will be enrolled and will similarly receive up to 6 cycles of treatment with the recommended Phase 2a dose of MG4101. The 2 subgroups are patients with indolent and aggressive NHL of B-cell origin respectively.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multi-center, Open-label, Phase 1/2a Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy With MG4101 Plus Rituximab in Patient With Relapsed/Refractory Non-Hodgkin's Lymphoma of B-cell Origin
Actual Study Start Date : November 28, 2018
Estimated Primary Completion Date : October 2019
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
Drug Information available for: Rituximab

Arm Intervention/treatment
Experimental: single arm
  1. Phase 1

    1. MG4101 (Allogeneic Natural Killer cell): i.v bi-weekly

      • Group 1: 1 x 10^7 cells/㎏
      • Group 2: 3 x 10^7 cells/㎏
      • Group 3: 9 x 10^7 cells/㎏
    2. Interleukin-2 (IL-2): s.c bi-weekly with MG4101 at 1X10^6 IU/m2 per day.
    3. Rituximab: 375mg/m2. i.v. weekly for the first 2 cycles only (8 doses). monthly (3-6 cycle)
    4. Lymphodepletion: Fludarabine 20mg/m2 + Cyclophosphamide 250 mg/m2 i.v. D-3, D-2, D-1 of 1st, 3rd, and 5th cycle
  2. Phase 2a Administration of recommended dosage of MG4101 determined from Phase 1 will be applied in Phase 2a. Dosage regimens for lymphodepletion, IL-2 and Rituximab will be the same as Phase 1.
Drug: Rituximab
weekly administration of Rituximab 375mg/m2 during cycle 1 and 2, monthly administration from cycle 3(up to cycle 6)
Other Name: Mabthera

Drug: Fludarabine
administration of fludarabine 20mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
Other Name: Fludara

Drug: Cyclophosphamide
administration of fludarabine 250mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
Other Name: Endoxan

Biological: MG4101(allogeneic Natural Killer cell)
administration every fortnight for each cycle, beginning with the 1st dose of rituximab for that cycle.

Drug: Interleukin-2
1 x 10^6 IU/m2, together with MG4101
Other Name: proleukin

Primary Outcome Measures :
  1. Phase I - Maximum Tolerated Dose of the dose of MG4101 in combination with Rituximab [ Time Frame: 28 days ]
    Dose-Limiting Toxicity assessment

  2. Phase II - Objective Response Rate [ Time Frame: up to 3 years ]
    central review by Positron Emission Tomograph-CT

Secondary Outcome Measures :
  1. Phase I - Objective Response Rate [ Time Frame: 1 years ]
    investigator review by Positron Emission Tomograph-CT

  2. Phase II - Complete Response [ Time Frame: up to 3 years ]
    Complete Response Rate

  3. Phase II -Partial Response [ Time Frame: up to 3 years ]
    Partial Response rate

  4. Phase II - Overall Survival [ Time Frame: up to 3 years ]
    every 12 weeks after End Of Treatment

  5. Phase II - Time To Progression [ Time Frame: up to 3 years ]
    every 12 weeks after End Of Treatment

  6. Phase II - Time to Response [ Time Frame: up to 3 years ]
    every 12 weeks after End Of Treatment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with relapsed or refractory NHL of B-cell origin (mature B cell lymphoma according to WHO)* who are not considered candidates for intensive anti-lymphoma therapy.
  2. Patients must have received at least 1 prior systemic treatment including anti-CD20 therapy but have received no more than 4 systemic treatments and have:

    1. Relapse/Progression and is not considered as a candidate for autologous stem-cell transplantation or high-dose immuno-chemotherapy with allogenic antibody transplantation.
    2. Or Relapsed/progressed after high-dose immuno-chemotherapy with autologous stem-cell transplantation.
    3. Or Relapsed/progressed after homoplastic stem-cell transplantation performed at least 12 weeks ago from C1V1.

      • For Phase 1 - Any subtype can be enrolled. For Phase 2a - Only below subtype can be enrolled in each group. I. Indolent B-cell NHL: Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma and Marginal Zone Lymphoma II. Aggressive B-cell NHL: Diffuse Large B-cell Lymphoma De novo and Diffuse Large B-cell Lymphoma transformed
  3. According to Positron Emission Tomograph(PET)-CT screening, patients having lesion/nodules ≥1 with major axis longer than 1.5 cm and the boundaries are clearly shown.
  4. Eastern Cooperative Oncology Group score 0 or 1
  5. 20 years or older. Age limit for Phase 1 is 65 and for Phase 2a 80.
  6. Expected lifespan ≥ 3 month
  7. Patients signed Informed consent form
  8. Earlier documented result that showed that the patient is positive for CD20 via immunophenotyping within 6 months of C1V1
  9. Toxicities due to prior therapy must be stable and recovered to ≤ Grade 1 (except for clinically non-significant toxicities such as alopecia)
  10. Those patients who satisfied with following criteria in blood testing, kidney function test and liver function test:

    1. Absolute neutrophil count: Absolute Neutrophil Count ≥ 1,000/ µL (Growth factor support at least 2 weeks prior to C1V1)
    2. Haemoglobin level ≥ 8g/㎗ (Blood transfusion at least 2 weeks prior to C1V1)
    3. Platelet count ≥75,000/µL (Growth factor support/blood transfusion at least 2 weeks prior to C1V1)
    4. Total bilirubin < 3.0㎎/㎗
    5. Aspartate aminotransferase(AST) or Alanine Aminotransferase(ALT) ≤ 2.5 x upper normal limit (UNL)
    6. Creatinine clearance (as estimated by Cockcroft Gault) ≥ 30 mL/min

Exclusion Criteria:

  1. Patients considered appropriate to have stem-cell transplantation after high-dose chemotherapy as salvage therapy.
  2. Patient with Central Nervous System(CNS) lymphoma or any involvement of the CNS.
  3. Patients who had a prior history of another malignancy over the last 5 years.
  4. Patients with impaired organ functions deemed as significant by investigators.
  5. Patients who had prior allogeneic Natural Killer cell treatment.
  6. Chronic or active infectious diseases required to be treated at the time of Investigational Product administration, including Cytomegalovirus(CMV) prophylactic therapy.
  7. Had human immunodeficiency virus (HIV)-positive serology.
  8. HBsAg or Hepatitis B virus(HBV) DNA positive or had Hepatitis C virus(HCV) antibodies
  9. Patients who received anti-CD20 cancer chemotherapy or immunoglobulin within 4 weeks of C1V1.
  10. Patients who received another investigational drug within 4 weeks of C1V1.
  11. Patients with acute graft-versus-host disease(GvHD) ≥Grade 3 or extensive chronic GvHD within 2 weeks of C1V1.
  12. High-dose stem cell support treatment carried out within 6 months of C1V1.
  13. Radioimmunotherapy within 4 weeks of C1V1.
  14. Patients with major surgery within 4 weeks of C1V1.
  15. Patients required to have treatment as having severe diseases such as severe heart failure or uncontrolled severe heart disease and considered not to be appropriate to participate in this trial by investigator's decision.
  16. Patients on enzyme inducing agents.
  17. Patients who have a plan to have vaccination during the trial.
  18. Patients with sensitivity to Interleukin-2, cyclophosphamide or fludarabine.
  19. Patients with urinary outflow obstruction
  20. Patients with history of abnormal cardiac or pulmonary function tests in 6 months prior to screening visit (Clinically Significant)
  21. Patients with history of solid organ allografts
  22. Patients with pre-existing or initial presentation of autoimmune disease or inflammatory disorders, such as Crohn's disease, scleroderma, thyroiditis, inflammatory arthritis, diabetes mellitus, oculo-bulbar myasthenia gravis, crescentic Immunoglobulin A(IgA) glomerulonephritis, cholecystitis, cerebral vasculitis, Stevens-Johnson syndrome and bullous pemphigoid, due to possible exacerbation with IL-2
  23. Concomitant treatment with other cardiotoxic inducing agents
  24. Patients who are allergic to Rituximab, Rituximab's excipient (sodium citrate, polysorbate 80, sodium chloride, sodium hydroxide, hydrochloric acid) or other proteins same as Rituximab.
  25. From the day of participation of this trial to 12 months from the day of final administration of Investigational Product, patients who are unable or unwilling to use appropriate contraceptive methods. (Condom, diaphragm, Intrauterine Device, hormonal oral contraceptive use, or male partner with vasectomy)
  26. Pregnant or lactating women. (Breast-feeding cannot be done within 12 months after final Investigational Product administration)
  27. Patients suspected to have currently known or suspected alcohol abuse or drug abuse according to investigator's decision.
  28. According to investigator's judgement, protocols cannot be followed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03778619

Layout table for location contacts
Contact: Kunhee Choi +82-31-260-0857

Layout table for location information
Korea, Republic of
Asan Medical Center Not yet recruiting
Seoul, Korea, Republic of
Contact: Cheol-Won Suh, MD. PhD         
Principal Investigator: Cheol-Won Suh, MD. PhD         
Samsung Medical Center Recruiting
Seoul, Korea, Republic of
Contact: Won Seog Kim, MD. PhD.         
Principal Investigator: Won Seog Kim, MD. PhD.         
Seoul National Univ. Hospital Recruiting
Seoul, Korea, Republic of
Contact: Youngil Koh, MD. PhD.         
Principal Investigator: Youngil Koh, MD. PhD.         
Sponsors and Collaborators
Green Cross LabCell Corporation
Layout table for investigator information
Principal Investigator: Won Seog Kim, Dr. Samsung Medical Center

Layout table for additonal information
Responsible Party: Green Cross LabCell Corporation Identifier: NCT03778619     History of Changes
Other Study ID Numbers: MG4101-NHL-P1
First Posted: December 18, 2018    Key Record Dates
Last Update Posted: December 19, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Fludarabine phosphate
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antineoplastic Agents, Immunological
Antimetabolites, Antineoplastic
Antiviral Agents
Anti-Infective Agents
Analgesics, Non-Narcotic